Navigation Links
Shire's ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
Date:2/13/2008

Mexico is the First Latin American Country to Approve Treatment

BASINGSTOKE, England and CAMBRIDGE, Massachusetts, February 13 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP)(NASDAQ: SHPGY)(TSX: SHQ), the global specialty biopharmaceutical company, announced that ELAPRASE(R) (idursulfase), a human enzyme replacement therapy for the treatment of Hunter syndrome, has been approved for commercial sale by the Mexican Federal Commission for the Protection against Sanitary Risk (COFEPRIS). Mexico is the tenth-largest pharmaceutical market in the world(1) and the first Latin American country to approve ELAPRASE.

Hunter syndrome, also known as Mucopolysaccharidosis II (MPS II), is a serious, life-threatening genetic condition mainly affecting males that results from an absence of, or deficiency in, the lysosomal enzyme iduronate-2-sulfatase. Without sufficient amounts of this enzyme, cellular waste products accumulate in tissues and organs, which then begin to malfunction, leading to severe clinical complications and early mortality.

ELAPRASE, developed by Shire Human Genetic Therapies (HGT), is the first and only enzyme replacement therapy approved for people suffering from Hunter syndrome. The medicine is given as a weekly infusion and is designed to replace the deficient iduronate-2-sulfatase enzyme.

"The approval of ELAPRASE in Mexico marks a significant milestone because for the first time, Hunter syndrome patients in Mexico have access to treatment," said Sylvie Gregoire, President of Shire HGT, the Shire business unit focused on genetic diseases. "This approval also underscores our dedication and commitment to provide meaningful treatments for patients suffering from serious and often neglected diseases around
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
2. Genzyme Receives Approval to Market Elaprase(R) in Japan
3. Clexane(R)/Lovenox(R) Approved in Japan
4. EVICEL(TM) Fibrin Sealant (Human) Approved for General Hemostasis in Surgery
5. Avastin Approved in Europe for First-Line Treatment of Patients With Advanced Kidney Cancer
6. Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension
7. Healthcare Announced That an Overwhelming Majority of its Shareholders Approved the NexGen Biofuels Transaction
8. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
9. Biomoda Announces Collaborative Agreement With New Mexico Tech
10. Viramontes to Lead PPD Clinical Operations in Mexico, Central America and the Caribbean
11. Prestigious Bioethics Award for Scholar from Mexico
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... , May 1, 2015 /CNW/ - Softchoice, a leading North ... it is the proud recipient of two Cisco® Partner Summit ... Partner of the Year and Security Partner of the Year ... conference taking place this week in Montreal ... one, but two Cisco partner awards at this year,s conference," ...
(Date:5/1/2015)... ALBANY, N.Y. , May 1, 2015 ... today that William S. Marth , AMRI,s President ... of America Merrill Lynch 2015 Health Care Conference on ... A live audio webcast of the presentation can ... http://ir.amriglobal.com/events.cfm?CalendarID=2          The webcast will be ...
(Date:4/30/2015)... 2015 Spirax Sarco, the leader in ... to announce that for the first time in the ... of a Queen’s Award for Innovation – the UK’s ... manufacture of a unique flowmeter. , The Spirax Sarco ... traditional steam flow measurement. The device provides reliable, ...
(Date:4/30/2015)... 2015 Cytokinetics, Incorporated (Nasdaq: CYTK) reported total ... were $4.4 million, compared to $8.0 million during the same ... quarter was $8.9 million, or $0.23 per basic and diluted ... same period in 2014, of $8.7 million, or $0.27 per ... cash, cash equivalents and investments totaled $117.5 million. , ...
Breaking Biology Technology:Softchoice recognized with two Country Awards at Cisco Partner Summit 2015 2AMRI to Present at the Bank of America Merrill Lynch 2015 Health Care Conference 2Spirax Sarco Receives a Queen’s Award for Innovation 2Spirax Sarco Receives a Queen’s Award for Innovation 3Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 2Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 3Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 4Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 5Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 6Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 7Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 8
... of mortality faced by patients at ... the national average, EL SEGUNDO, Calif., July 7 ... for those diagnosed with chronic,kidney failure and disease (CKD), ... validated by both the Clinical,Performance Measures Report published in ...
... VANCOUVER, July 7 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals,Inc. ("Angiotech") ... specialty,pharmaceutical and medical device company, today announced the ... notes listed below (the "Notes"),in an amount that ... and unpaid interest and the "Early Tender Premiums" ...
... EVRY, France, July 7 The board of directors ... created in 1990 by the AFM,(French Muscular Dystrophy Association). ... hand over the reins after heading the,laboratory between 1990 ... Yves Champey is a physician by training. Genethon will ...
Cached Biology Technology:Superior Patient Clinical Outcomes Confirms DaVita's Leadership Position on Quality Dialysis Care 2Superior Patient Clinical Outcomes Confirms DaVita's Leadership Position on Quality Dialysis Care 3Angiotech To Commence Cash Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014 2Angiotech To Commence Cash Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014 3Angiotech To Commence Cash Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014 4Angiotech To Commence Cash Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014 5Angiotech To Commence Cash Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014 6Angiotech To Commence Cash Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014 7Angiotech To Commence Cash Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014 8A New President at the Head of the Genethon Laboratory 2
(Date:4/2/2015)... HAMBURG, Germany , April 2, 2015 /PRNewswire/ ... ten fingerprint tests DERMALOG by far outperforms the ... While always maintaining high accuracy, the system is ... second. Hence, the speed proves up to be ... 40% faster than its runner-up performance. ...
(Date:4/2/2015)... , April 2, 2015 ... touch fingerprint sensor FPC1025 from the distributor World Peace ... commence during Q2 2015 although the major part of ... sensors will be used by smartphone manufacturers in ... MSEK is included in the communicated revenue guidance of ...
(Date:3/31/2015)... -- Elephant Talk Communications Corp. (NYSE MKT: ETAK) ("Elephant Talk" ... Network Architecture (ET Software DNA® 2.0) platforms and cyber ... million for the year ended December 31, 2014 as ... ended December 31, 2013. At the ... multi-year transition away from its legacy landline business to ...
Breaking Biology News(10 mins):DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6
... of California, Riverside have made a discovery in the ... drugs and explore novel strategies for treating seizures associated ... Americans. Neurons, the basic building blocks of the ... and chemical signaling. During epileptic seizures, which generally ...
... Mike Jaffe,s recent book chapter about sugar-based chemicals ... series, must-read list. "Sugar-Based Chemicals for Environmentally ... Symposium Series http://pubs.acs.org/doi/abs/10.1021/bk-2010-1061.ch001 and is racking ... doctoral student and research professors A. J. East ...
... This month in ecological science, researchers evaluate the U.S. National ... in the return of a native lizard to the Ozarks ... us about the Arctic Tundra,s fire regime. These articles ... Ecological Society of America,s (ESA) journals. Taking ...
Cached Biology News:UC Riverside neuroscientists' discovery could bring relief to epilepsy sufferers 2Sugar-based chemicals book chapter by NJIT professor takes ACS kudos 2US National Fire Plan, return of Ozark lizard and the Arctic Tundra's fire regime 2US National Fire Plan, return of Ozark lizard and the Arctic Tundra's fire regime 3
... Colorimetric Detection System is intended for use ... generated by an in-house validated in vitro ... of interest. • ... a hybridization capture assay designed to detect ...
... Ideal for cell culture scale-up, these ... 10 7 - 10 9 range ... bottles or spinner flasks. • High mechanical ... leak tested prior to shipping • Certified ...
BD BioCoat Collagen IV 150 mm Culture Dishes...
Gridded Cell Culture Petri Dish (20 mm molded in base), tissue-culture treated...
Biology Products: